These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 11137181

  • 1. Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function.
    Di Mauro M, Papalia G, Le Moli R, Nativo B, Nicoletti F, Lunetta M.
    Diabetes Res Clin Pract; 2001 Jan; 51(1):45-50. PubMed ID: 11137181
    [Abstract] [Full Text] [Related]

  • 2. Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients.
    Lunetta M, Di Mauro M, Le Moli R, Nicoletti F.
    Diabetes Res Clin Pract; 1997 Nov; 38(2):81-9. PubMed ID: 9483371
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin.
    Lunetta M, Di Mauro M, Le Moli R.
    J Endocrinol Invest; 1997 Jun; 20(6):331-4. PubMed ID: 9294779
    [Abstract] [Full Text] [Related]

  • 6. Assessment of hepatic insulin action in obese type 2 diabetic patients.
    Staehr P, Hother-Nielsen O, Levin K, Holst JJ, Beck-Nielsen H.
    Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
    [Abstract] [Full Text] [Related]

  • 7. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S.
    N Engl J Med; 1992 May 14; 326(20):1316-22. PubMed ID: 1348845
    [Abstract] [Full Text] [Related]

  • 8. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake.
    Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA.
    Diabetes; 1998 Nov 14; 47(11):1735-47. PubMed ID: 9792543
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
    Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA.
    Diabetes; 2000 Apr 14; 49(4):611-7. PubMed ID: 10871199
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.
    Diabetes Care; 1996 Jun 14; 19(6):580-6. PubMed ID: 8725855
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.
    Orskov L, Alberti KG, Mengel A, Møller N, Pedersen O, Rasmussen O, Seefeldt T, Schmitz O.
    Diabetologia; 1991 Jul 14; 34(7):521-6. PubMed ID: 1916058
    [Abstract] [Full Text] [Related]

  • 16. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans.
    Luzi L, DeFronzo RA.
    Am J Physiol; 1989 Aug 14; 257(2 Pt 1):E241-6. PubMed ID: 2669517
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
    Henriksen JE, Levin K, Thye-Rønn P, Alford F, Hother-Nielsen O, Holst JJ, Beck-Nielsen H.
    Diabetes; 2000 Jul 14; 49(7):1209-18. PubMed ID: 10909980
    [Abstract] [Full Text] [Related]

  • 19. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus.
    Luzi L, Hering BJ, Socci C, Raptis G, Battezzati A, Terruzzi I, Falqui L, Brandhorst H, Brandhorst D, Regalia E, Brambilla E, Secchi A, Perseghin G, Maffi P, Bianchi E, Mazzaferro V, Gennari L, Di Carlo V, Federlin K, Pozza G, Bretzel RG.
    J Clin Invest; 1996 Jun 01; 97(11):2611-8. PubMed ID: 8647955
    [Abstract] [Full Text] [Related]

  • 20. Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production.
    Toft I, Jenssen T.
    Scand J Clin Lab Invest; 2005 Jun 01; 65(4):307-20. PubMed ID: 16076686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.